Scottsdale, AZ– November 29th, 2018 - RenovaCare, Inc., (Symbol: RCAR; www.renovacareinc.com) today announced an equity financing for $15.5 million from Kalen Capital Corporation, the family office of Mr. Harmel S. Rayat, majority shareholder and Chairman of RenovaCare. This increases his family office’s total equity investment in RenovaCare since 2013 to over $20 million.
Scottsdale, AZ - October 26, 2018 - RenovaCare, Inc., (OTC: RCAR),developer of patented technologies* for isolating and spraying a patient’s own stem cells onto burns and wounds for rapid self-healing, today announced the appointment of Mr. Steve Yan-Klassen, CPA, CMA, as its Chief Financial Officer.
RenovaCare, Inc., (RCAR), announces the appointment of Mr. Harmel S. Rayat, longtime majority stockholder, as Chairman of its Board of Directors.
RenovaCare, Inc., (RCAR), announces that it has received video evidence showing what appears to be predatory trading practices of several FINRA member firms in its stock.
RenovaCare, Inc., (RCAR), today announced new initiatives to expand its product pipeline and associated clinical indications beyond severe second-degree burns.
RenovaCare, Inc., (RCAR), announced it has decisively won against patent challenger, Avita Medical, in a proceeding at the United States Patent Office (USPTO).
RenovaCare (RCAR) announces positive outcomes from its pre-submission meeting with the United States Food and Drug Administration (FDA) regarding the RenovaCare SkinGun™ and CellMist™ Systems.
RenovaCare (OTCQB: RCAR) today issued a strong rejection to Streetsweeper, known for spreading “short and distort” commentary on companies it targets for short selling, in this case RenovaCare.
New York, Pittsburgh & Berlin – January 30, 2018 – RenovaCare, Inc., (OTCQB: RCAR), today highlighted an analysis of treatment results from 44 patients treated for severe second-degree wide-area burn injuries, as published in Burns, the peer-reviewed Journal of the International Society for Burn Injuries. The treatment method, which involved isolating and spraying the patient’s own skin stem cells on to burn wounds, is the technology underlying the RenovaCare patented SkinGun™* and CellMist™ System*.
New York, Pittsburgh & Berlin – January 9th, 2018 – RenovaCare, Inc., (OTCQB: RCAR), developer of the SkinGun™ and CellMist™ System for isolating and spraying a patient’s own stem cells onto burns and wounds for rapid self-healing, is pleased to provide its outlook for 2018, which includes a shareholder update on the Company’s plans to…
